Нарушение функции нижних мочевых путей у мужчин с гипогонадизмом и метаболическим синдромом

Нарушение функции нижних мочевых путей у мужчин с гипогонадизмом и метаболическим синдромом

Автор: Старцев В.Ю., Иванов Н.В., Дударев В.А.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Андрология

Статья в выпуске: 1, 2019 года.

Бесплатный доступ

В обзорной статье отражен современный взгляд на взаимосвязь возрастного гипогонадизма, метаболического синдрома (МС), и симптомов нижних мочевых путей (СНМП) у мужчин. Как правило, СНМП у мужчин пожилого возраста рассматриваются как проявление гиперплазии предстательной железы. Выделена корреляционная зависимость между объемом предстательной железы (ПЖ) и компонентами МС, однако СНМП рассматривают как полиэтиологическое заболевание. Согласно данным мета-анализов, снижение уровня тестостерона (Т), дислипидемия и инсулинорезистентность (ИР) рассматриваются в качестве причины нарушения качества мочеиспускания у мужчин пожилого возраста. Эти синдромы обусловливают иные, патологические обменные процессы в нижних мочевых путях, приводя к структурным нарушениям в тканях ПЖ, стенке мочевого пузыря, сосудах и нервных окончаниях. Тестостерон-заместительная терапия (ТЗТ), используемая у мужчин с гипогонадизмом, оказывает положительное влияние на компоненты МС, а также снижает дисфункцию нижних мочевых путей. Остается дискуссионным вопрос об эффективности и безопасности ТЗТ для коррекции нарушений мочеиспускания у мужчин с гипогонадизмом, что составляет важную медико-социальную проблему и требует дальнейшего ее изучения. Авторы заявляют об отсутствии конфликта интересов.

Еще

Тестостерон, метаболический синдром, гиперплазия предстательной железы, тестостерон-заместительная терапия, гипогонадизм

Короткий адрес: https://sciup.org/142220516

IDR: 142220516   |   DOI: 10.29188/2222-8543-2019-11-1-95-100

Список литературы Нарушение функции нижних мочевых путей у мужчин с гипогонадизмом и метаболическим синдромом

  • Cheng CL, Groat de WC. Effect of orchiectomy and testosterone replacement on lower urinary tract function in anesthetized rats. Am J Physiol Renal Physiol. 2016;311:F864-F870 DOI: 10.1152/ajprenal.00016.2016
  • Vignozzi L, Gacci M, Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol. 2016;13:108-1193 DOI: 10.1038/nrurol.2015.301
  • Zitzmann M. Testosterone deficiency, insulin resistance and the metabolic syndrome. Nat Rev Endocrinol. 2009;5:673-681 DOI: 10.1038/nrendo.2009.212
  • Maneschi E, Morelli A, Filippi S, Cellai I, Comeglio P, Mazzanti B, et al. Testosterone treatment improves metabolic syndrome-induced adipose tissue derangements. J Endocrinol. 2012;215:347-362 DOI: 10.1530/JOE-12-0333
  • Grosman H, Fabre B, Lopez M, Scorticati C, Lopez Silva M, Mesch V, et al. Complex relationship between sex hormones, insulin resistance and leptin in men with and without prostatic disease. Aging Male. 2016;19:40-45 DOI: 10.3109/13685538.2015.1100600
  • Lee S, Min HG, Choi SH, Kim YJ, Oh SW, Kim YJ, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006;14:172-179
  • DOI: 10.1038/oby.2006.21
  • Muller RL, Gerber L, Moreira DM, Andriole G, Jr, Hamilton RJ, Fleshner N, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol. 2013;63:1115-1121
  • DOI: 10.1016/j.eururo.2013.02.038
  • Ryl A, Rotter I, Miazgowski T, Slojewski M, Dolfgowska B, Lubkowska A, et al. Metabolic syndrome and benign prostatic hyperplasia: association or coincidence? Diabetol Metab Syndr. 2015;7:94. 10.1186/s13098-015-0089-1
  • DOI: :10.1186/s13098-015-0089-1
  • Gorbachinsky I, Akpinar H, Assimos DG. Metabolic syndrome and urologic diseases. RevUrol. 2010;12:e157-e180. ttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3020279/
  • Keast JR, Saunders RJ. Testosterone has potent, selective effects on the morphology of pelvic autonomic neurons which control the bladder, lower bowel and internal reproductive organs of the male rat. Neuroscience. 1998;85:543-556. org/
  • DOI: 10.1016/S0306-4522(97)00631-3
  • Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8:272-283
  • DOI: 10.1111/j.1743-6109.2010.01991.x
  • Vignozzi L, Cellai I, Santi R, Lombardelli L, Morelli A, Comeglio P, et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J Endocrinol. 2012;214:31-43
  • DOI: 10.1530/JOE-12-0142
  • Ozer K, Horsanali MO, Gorgel SN, Horsanali BO, Ozbek E. Association between benign prostatic hyperplasia and neutrophil-lymphocyte ratio, an indicator of inflammation and metabolic syndrome. Urol Int. 2017;98:466-471. org/
  • DOI: 10.1159/000448289
  • Kseneva SI, Yurmazov ZA, Timofeev MS, Borodulina EV, Udut VV. Lower urinary tract symptoms in metabolic syndrome in young adults. Endocr Metab Immune Disord Drug Targets. 2018;18:230-234
  • DOI: 10.2174/1871530318666180213110539
  • Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, DeNunzio C, et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2015;115:24-31
  • DOI: 10.1111/bju.12728
  • Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Tubaro A, Gravas S, et al. The impact of central obesity on storage luts and urinary incontinence after prostatic surgery. Curr Urol Rep. 2016;17:61. 10.1007/s11934-016-0620-4
  • DOI: :10.1007/s11934-016-0620-4
  • Besiroglu H, Dursun M, Otunctemur A, Ozbek E. The association between triglyceride high density lipoprotein cholesterol ratio and benign prostate hyperplasia in non-diabetic patients:a cross-sectional study. Aging Male. 2017;20:198-204
  • DOI: 10.1080/13685538.2017.1303828
  • Kupelian V, McVary KT, Kaplan SA, Hall SA, Link CL, Aiyer LP, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J Urol. 2009;182:616-624
  • DOI: 10.1016/j.juro.2009.04.025
  • Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, Morgia G. Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia. BJU Int. 2010;106:1700-1703
  • DOI: 10.1111/j.1464-410X.2010.09459.x
  • Gacci M, Vignozzi L, Sebastianelli A, Salvi M, Giannessi C, De Nunzio C, et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 2013;16:101-106
  • DOI: 10.1038/pcan.2012.44
  • Fu Y, Zhou Z, Yang B, Zhang K, He L, Zhang X. The relationship between the clinical progression of benign prostatic hyperplasia and metabolic syndrome: a prospective study. Urol Int. 2016;97:330-335
  • DOI: 10.1159/000448484
  • Russo GI, Castelli T, Urzi D, Privitera S, Fragalà E, LaVignera S, et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Aging Male. 2015;18:207-216
  • DOI: 10.3109/13685538.2015.1062980
  • Gacci M, Corona G, Sebastianelli A, Serni S, DeNunzio C, Maggi M, et al. Male lower urinary tract symptoms and cardiovascular events: a systematic review and meta-analysis. Eur Urol. 2016;70:788-796. 10.1016/j.eururo.2016.07.007
  • DOI: :10.1016/j.eururo.2016.07.007
  • Kim YH, Kim JJ, Kim SM, Choi Y, Jeon MJ. Association between metabolic syndrome and pelvic floor dysfunction in middle-aged to older Korean women. Am J Obstet Gynecol. 2011;205:71.e1-71.e8
  • DOI: 10.1016/j.ajog.2011.02.047
  • Björntorp P, Rosmond R. The metabolic syndrome: a neuroendocrine disorder? Br J Nutr. 2000;83(Suppl 1):S49-S57. org/
  • DOI: 10.1017/S0007114500000957
  • Rohrmann S., Smit E., Giovannucci E., Platz E.A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III) Int J Obes 2005;29:310-316
  • DOI: 10.1038/sj.ijo.0802881
  • Gao Y, Wang M, Zhang H, Tan A, Yang X, Qin X, et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology. 2012;79:194-201
  • DOI: 10.1016/j.urology.2011.07.1399
  • Tsujimura A, Miyagawa Y, Takezawa K, Okuda H, Fukuhara S, Kiuchi H, et al. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology. 2013;82:814-819
  • DOI: 10.1016/j.urology.2013.06.023
  • Grosman H, Rosales M, Fabre B, Nolazco C, Mazza O, Berg G, et al. Association between testosterone levels and the metabolic syndrome in adult men. Aging Male. 2014;17:161-165
  • DOI: 10.3109/13685538.2014.913561
  • Moon H, Choi I, Kim S, Ko H, Shin J, Lee K, et al. Cross-sectional association between testosterone, sex hormone-binding globulin and metabolic syndrome: the healthy twin study. ClinEndocrinol (Oxf) 2017;87:523-531
  • DOI: 10.1111/cen.13390
  • Rodriguez A, Muller DC, Metter EJ, Maggio M, Harman SM, Blackman MR, et al. Aging, androgens, and the metabolic syndrome in a longitudinal study of aging. J Clin Endocrinol Metab. 2007;92:3568-3572
  • DOI: 10.1210/jc.2006-2764
  • Corona G, Vignozzi L, Sforza A, Mannucci E, Maggi M. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133
  • DOI: 10.1016/j.mce.2015.06.031
  • Maggio M, Lauretani F, Ceda GP, Bandinelli S, Basaria S, Paolisso G, et al. Estradiol and metabolic syndrome in older italian men: The InCHIANTI Study. J Androl. 2010;31:155-162
  • DOI: 10.2164/jandrol.108.006098
  • Antonio L, Wu FC, O'Neill TW, Pye SR, Carter EL, Finn JD, et al. Associations between sex steroids and the development of metabolic syndrome: a longitudinal study in European men. J Clin Endocrinol Metab. 2015;100:1396-1404
  • DOI: 10.1210/jc.2014-4184
  • Mitsuzuka K, Arai Y. Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 2018;25:45-53
  • DOI: 10.1111/iju.13473
  • Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, et al. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-1041. org/
  • DOI: 10.2337/diacare.27.5.1036
  • Bravo G, Massa H, Rose'Meyer R, Chess-Williams R, McDermott C, Sellers DJ. Effect of short-term androgen deficiency on bladder contractility and urothelial mediator release. Naunyn Schmiedebergs Arch Pharmacol 2017;390:547-556
  • DOI: 10.1007/s00210-017-1355-6
  • Schatzl G, Brössner C, Schmid S, Kugler W, Roehrich M, Treu T, et al. Endocrine status in elderly men with lower urinary tract symptoms: correlation of age, hormonal status, and lower urinary tract function. The Prostate Study Group of the Austrian Society of Urology. Urology. 2000;55:397-402. org/
  • DOI: 10.1016/S0090-4295(99)00473-2
  • Litman HJ, Bhasin S, O'Leary MP, Link CL, McKinlay JB. An investigation of the relationship between sex-steroid levels and urological symptoms: results from the Boston Area Community Health survey. BJU Int. 2007;100:321-326
  • DOI: 10.1111/j.1464-410X.2007.06938.x
  • Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III) Urology 2007;69:708-713
  • DOI: 10.1016/j.urology.2007.01.011
  • Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010;105:1554-1559
  • DOI: 10.1111/j.1464-410X.2009.09090.x
  • Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008;29:102-105
  • DOI: 10.2164/jandrol.107.002774
  • Shigehara K, Konaka H, Nohara T, Izumi K, Kitagawa Y, Kadono Y, et al. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study) Andrologia 2018;50
  • DOI: 10.1111/and.12815
  • Liu HY, Chung MS, Wang HJ, Liu RT, Chuang YC. Nocturia indicates a poor health status and increases mortality in male patients with type 2 diabetes mellitus. Int Urol Nephrol 2016;48:1209-1214. 10.1007/s11255-016-1310-3
  • DOI: :10.1007/s11255-016-1310-3
  • Yassin A, Nettleship JE, Talib RA, Almehmadi Y, Doros G. Effects of testosterone replacement the rapy with drawal and re-treatmentin hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male 2016;19:64-69
  • DOI: 10.3109/13685538.2015.1126573
  • Haider KS, Haider A, Doros G, Traish A. Long-term testosterone therapy improves urinary and sexual function, and quality of life in men with hypogonadism: results from a propensity matched subgroup of a controlled registry study. J Urol 2018;199:257-265
  • DOI: 10.1016/j.juro.2017.07.039
  • Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-1868
  • DOI: 10.1210/endo.140.4.6655
  • Tek M, Balli E, Cimen B, Efesoy O, Oguz I, Cayan S. The effect of testosterone replacement therapy on bladder functions and histology in orchiectomized mature male rats. Urology 2010;75:886-890. 10.1016/j.Urology.2009.08.016
  • DOI: :10.1016/j.urology.2009.08.016
  • Hristov KL, Parajuli SP, Provence A, Petkov GV. Testosterone decreases urinary bladder smooth muscle excitability via novel signaling mechanism involving direct activation of the BK channels. Am J Physiol Renal Physiol 2016;311:F1253-1259
  • DOI: 10.1152/ajprenal.00238.2016
  • Fernandes VS, Barahona MV, Recio P, Martmez-Saenz A, Ribeiro AS, Contreras C, et al. Mechanisms involved in testosterone-induced relaxation to the pig urinary bladder neck. Steroids 2012;77:394-402
  • DOI: 10.1016/j.steroids.2011.12.020
  • Kalinchenko S, Vishnevskiy EL, Koval AN, Mskhalaya GJ, Saad F. |Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 2008;11:57-61
  • DOI: 10.1080/13685530801953994
  • Karazindiyanoglu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146-149
  • DOI: 10.1080/13685530802290438
  • Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Muram D. Effects of testosterone level on lower urinary tract symptoms. Am J Mens Health 2016;10:440-442
  • DOI: 10.1177/1557988315590655
  • Morgentaler A, Traish AM. Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 2009;55:310-320
  • DOI: 10.1016/j.eururo.2008.09.024
  • Baas W, Köhler TS. Testosterone replacement therapy and voiding dysfunction. Transl Androl Urol 2016;5:890-897
  • DOI: 10.21037/tau.2016.08.11
  • Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014;83:167-173
  • DOI: 10.1016/j.urology.2013.08.019
  • Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term t estosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism: a real-life observational registry study setting comparing treated and untreated (control) groups. J Cardiovasc Pharmacol Ther 2017;22:414-433
  • DOI: 10.1177/1074248417691136
  • Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in lateonse thypogonadism patients. Aging Male 2010;13:242-246
  • DOI: 10.3109/13685538.2010.487552
  • Shigehara K, Konaka H, Koh E, Izumi K, Kitagawa Y, Mizokami A, et al. Effects of testosterone replacement therapy on nocturia and quality of life in men with hypogonadism: a subanalysis of a previous prospective randomized controlled study in Japan. Aging Male 2015;18:169-174
  • DOI: 10.3109/13685538.2015.1038990
  • Gallo CB, Miranda AF, Felix-Patricio B, Ramos CF, Cardoso LE, Costa WS et al. Effects of castration and hormone replacement in the urinary bladder of rats: structural, ultrastructural, and biochemical analysis. J Androl 2012;33:684-690
  • DOI: 10.2164/jandrol.111.014159
  • Morelli A, Comeglio P, Filippi S, Sarchielli E, Cellai I, Vignozzi L et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J Steroid Biochem Mol Biol 2012;132:80-92. 10.1016/j.jsbmb.2012.02.007
  • DOI: :10.1016/j.jsbmb.2012.02.007
  • Cohen PG. Abdominal obesity and intra-abdominal pressure: a new paradigm for the pathogenesis of the hypogonadal-obesity-BPH-LUTS connection. Horm Mol Biol Clin Investig 2012;11:317-320
  • DOI: 10.1515/hmbci-2012-0030
  • Yucel C, Keskin MZ, Peskircioglu CL. The effect of transdermal testosterone administration on lower urinary tract symptoms and erectile dysfunction: a prospective, randomized, placebo-controlled trial. Curr Urol 2017;11:4-8
  • DOI: 10.1159/000447187
Еще
Статья обзорная
QR-код для установки приложения SciUp Наведите камеру и скачайте бесплатное приложение SciUp